Jupiter Asset Management Ltd. Has $16.72 Million Position in Eli Lilly and Company $LLY

Jupiter Asset Management Ltd. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,449 shares of the company’s stock after purchasing an additional 390 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Eli Lilly and Company were worth $16,720,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at about $27,000. Blume Capital Management Inc. grew its stake in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the last quarter. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at $35,000. TD Capital Management LLC raised its position in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $54,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their price target for the company from $886.00 to $1,104.00 in a research note on Monday. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Guggenheim restated a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $981.89.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,018.28 on Thursday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,022.42. The business has a 50-day simple moving average of $815.33 and a 200 day simple moving average of $778.16. The firm has a market capitalization of $962.67 billion, a price-to-earnings ratio of 66.55, a PEG ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the business earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.